BUZZ-EVgo stock surges due to LS Power's acquisition offer
路透社2026/11/02 14:17November 2 - ** Shares of electric vehicle charging company EVgo (EVGO.O) rose 45.2% in pre-market trading to $1.83.
** If the rally holds, the stock is set for its biggest single-day gain since October 2024.
** U.S. Securities and Exchange Commission (SEC) filings show that private company LS Power Equity Advisors will acquire EVgo (link).
** LS Power holds about 178 million shares of EVGO, representing 56% of voting securities.
** The proposed deal values EVGO at $2 per share in cash.
** As of the previous trading session’s close, the stock was down 56.7% year-to-date.
(To assist non-English speakers, Reuters has automated the translation of its report into several languages. As automated translation may contain errors or may not convey the intended context, Reuters does not guarantee the accuracy of automated translation. Automated translation is provided solely for the convenience of readers. Reuters assumes no responsibility for any loss or damage arising from the use of automated translation.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump Media & Technology Group plunges over 24%, hitting a new low since listing.
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.